Company: PSTV
Filing Date: 2025-04-11
Form Type: POS AM
Source: 0001193125-25-079109
Chunk: 8

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-11
Form: POS AM
Chunk 8
---
 to you in making your investment decision. Before investing in our shares of common stock, you should carefully read the entire prospectus, including the information set forth under the heading “ Risk Factors” and the financial statements and related notes and other information that we incorporate by reference herein, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. See also the sections below entitled “ Where You Can Find Additional Information” and “Information Incorporated by Reference.” Unless the context indicates otherwise, references in this prospectus to “Plus Therapeutics,” “we,” “our” and “us” refer, collectively, to Plus Therapeutics, Inc., a Delaware corporation, and its subsidiary taken as a whole.

Our Company

Overview

Plus Therapeutics is a U.S. pharmaceutical
company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (“CNS”) cancers. Our novel radioactive drug formulations, medical devices and therapeutic candidates are designed to deliver safe
and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres. Our formulations are
intended to achieve elevated patient-absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal
tissue/organ exposure and improved safety margins.

Our lead radiotherapeutic candidate,
REYOBIQ (rhenium (Re) obisbemeda), is designed specifically for CNS cancers including recurrent glioblastoma, leptomeningeal
metastases, and pediatric brain cancers by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery and
intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, is designed to treat many solid organ cancers
including primary and secondary liver cancers by intra-arterial injection.

On April 26, 2024, we acquired the cerebrospinal fluid cancer diagnostic
portfolio known as the “CNSide Platform” that is currently being utilized in the ReSPECT-LM clinical trial funded by the Cancer Prevention and Research Institute of Texas. We are
planning for the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test, which is a laboratory developed